Conditions: Alzheimer's Disease
Keywords: Rivastigmine, Alzheimer's disease, Transdermal patch
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 216
Healthy volunteers: no

Brief summary:
To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Active Comparator intervention 2: ENA713
Intervention descriptions: intervention 1: 1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day. intervention 2: -3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.

Protocol document: